Approved Hospital Formulary
Show Therapeutic Classes
QR Code Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:

trospium-xanomeline

trospium-xanomeline
Brand names: Cobenfy
Form Strength
CAPSULE, ORAL 20 mg-50 mg; 20 mg-100 mg; 30 mg-125 mg


Additional Information:

Formulary Restriction

  • Initiated by psychiatrist or continuation of home therapy 
  • If new start, confirmed insurance coverage outpatient 
  • Unable to tolerate movement, metabolic, and/or immune side effects of other antipsychotics
  • Failure of at least one antipsychotic with lower side effect burden* 
    • Aripiprazole 
    • Brexpiprazole 
    • Cariprazine 
    • Lumateperone 
    • Other partial D2 agonist  

Note: Xanomeline-trospium has not been studied in treatment-resistant patients with schizophrenia or as adjunctive therapy as these populations were excluded from clinical trials 

 


Last updated: Apr. 22, 2025







This site is intended for the staff of Legacy Health.
While others may view accessible pages, Legacy Health makes no warranty, express or implied,
as to the use of this information outside of Legacy Health.